Atreca Inc
F:0C1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Swatch Group AG
OTC:SWGAY
|
CH |
Atreca Inc
Capital Expenditures
Atreca Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Atreca Inc
F:0C1
|
Capital Expenditures
-$890k
|
CAGR 3-Years
36%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$563m
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$437.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
|
Atreca Inc
Glance View
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.
See Also
What is Atreca Inc's Capital Expenditures?
Capital Expenditures
-890k
USD
Based on the financial report for Dec 31, 2022, Atreca Inc's Capital Expenditures amounts to -890k USD.
What is Atreca Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
8%
Over the last year, the Capital Expenditures growth was 97%. The average annual Capital Expenditures growth rates for Atreca Inc have been 36% over the past three years , 8% over the past five years .
